Drug Profile
Research programme: therapeutic agents - Pharmacopeia/Schering-Plough
Alternative Names: PS 015146; PS 241541Latest Information Update: 24 Dec 2008
Price :
$50
*
At a glance
- Originator Schering-Plough
- Developer Pharmacopeia; Schering-Plough
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease; Cancer; Inflammation; Metabolic disorders; Respiratory tract disorders; Unspecified
Most Recent Events
- 23 Dec 2008 Pharmacopeia has been acquired by Ligand Pharmaceuticals
- 19 Apr 2007 Another candidate has been selected by Schering-Plough for preclinical development
- 17 Apr 2007 Preclinical trials in Undefined indication in USA (unspecified route)